(2023)
Effect of ramucirumab plus paclitaxel in advanced gastric cancer according to the status of programmed cell death-ligand 1 (PD-L1) expression.
JOURNAL OF GASTROINTESTINAL ONCOLOGY.
14,
6
(2023)
The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer.
JOURNAL OF GASTROINTESTINAL ONCOLOGY.
14,
6
(2023)
Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes.
JOURNAL OF GASTROINTESTINAL ONCOLOGY.
14,
5
(2023)
Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.
Oncology Research.
31,
6
(2023)
Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study.
ANTICANCER RESEARCH.
43,
9
(2023)
Tumor mutation burden in gastro-entero-pancreatic- neuroendocrine neoplasms.
JOURNAL OF GASTROINTESTINAL ONCOLOGY.
14,
4
(2023)
The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer.
JOURNAL OF GASTRIC CANCER.
23,
3
(2023)
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY.
-,
-
(2023)
Imatinib in c‑KIT‑mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18‑05 Trial).
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS.
-,
-
(2022)
Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY.
-,
-
(2022)
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Clinical Oncology.
34,
8
(2022)
Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors.
CANCERS.
14,
14
(2022)
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.
JOURNAL FOR IMMUNOTHERAPY OF CANCER.
10,
7
(2022)
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER.
10,
7
(2022)
Clinical Significance of Preoperative Hematological Parameters in Patients with D2‐Resected, Node‐Positive Stomach Cancer.
BIOMEDICINES.
10,
7
(2022)
Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer.
ANNALS OF SURGICAL ONCOLOGY.
-,
-
(2022)
HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer.
FRONTIERS IN ONCOLOGY.
12,
(2022)
Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial.
JOURNAL OF CANCER.
13,
4
(2021)
The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers.
FRONTIERS IN ONCOLOGY.
(2021)
Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT.
특허/프로그램
위암 아형의 분류 방법 (Methods for classifying subunits of gastric cancer).
10-2016-0048347.
20181204.
대한민국
